Amylyx Pharmaceuticals, Inc..
AMLX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel treatments for neurodegenerative diseases. Their primary focus is on developing therapies for amyotrophic lateral sclerosis (ALS) and other neurological disorders. The company's lead product...Show More
Better Health for All
20
Amylyx Pharmaceuticals' entire business is devoted to improving health outcomes for severe neurodegenerative diseases. While its lead product, Relyvrio for ALS, was found ineffective in a Phase 3 trial
1
and voluntarily withdrawn from the U.S. and Canadian markets as of April 4, 2024,
2
the company is entirely focused on developing therapies for other serious conditions like Wolfram syndrome and progressive supranuclear palsy, and a new ALS candidate
3
. The Phase 2 HELIOS trial for AMX0035 in Wolfram syndrome showed sustained stabilization or improvement in multiple outcomes at Week 48
4
and was generally well-tolerated with mild or moderate adverse events and no serious treatment-related adverse events
5
. The company's R&D expenses were $24.2 million in Q1 2023, representing approximately 33.9% of its product revenue, all dedicated to health improvement
6
. Amylyx demonstrated industry-leading risk transparency by publicly promising to withdraw Relyvrio if it failed
7
and fulfilling that promise, with results to be shared publicly
8
. Despite Relyvrio's annual price of $158,000,
9
the company committed to no copay for commercially insured patients, free access for uninsured, and a free drug program for existing patients after withdrawal, providing the drug at no cost through patient assistance programs
10
. The company focuses on rare diseases
11
and has programs to include people with ALS not typically eligible for clinical trials
12
and to help the undiagnosed
13
. Amylyx complies with global privacy and data security requirements, including GDPR,
14
and adheres to Good Clinical Practices, designing trials in collaboration with patients and caregivers
15
.
Fair Money & Economic Opportunity
0
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases. Its core business involves the research, development, and sale of pharmaceutical products, not financial services such as lending, insurance, or money management. Therefore, all KPIs related to financial products, services, and their associated metrics (e.g., APRs, loan books, credit scores, financial literacy programs, debt burden ratios, or open banking APIs) are not applicable to its operations. The company does not offer lending or deposit services to consumers, nor does it generate customer finance data or revenue from high-cost financial products. While the company does offer programs to ensure patients have no copay costs and provides drugs at no cost to uninsured/underinsured patients meeting financial eligibility criteria, these are related to drug access, not financial inclusion initiatives as defined by the rubric's focus on loan/insurance books or financial services.
1
Fair Pay & Worker Respect
10
Amylyx Pharmaceuticals has an overall employee satisfaction rating of 3.975 out of 5 stars, which equates to 79.5% engagement.
1
There is no evidence of any substantiated labor-law or human-rights violations, regulatory actions, or fines in the past three years.
2
Fair Trade & Ethical Sourcing
0
The provided corporate compliance statement emphasizes ethical conduct and a 'speak up' culture, detailing a process for reporting potential violations and referencing compliance with California Health and Safety Codes.
1
However, it does not contain any specific, quantitative data points or metrics related to fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.
2
Therefore, no KPIs can be scored based on the evidence provided.
Honest & Fair Business
-30
Amylyx Pharmaceuticals provides a whistleblower hotline and online portal, stating a commitment to a 'speak up' culture and serious handling of violations.
1
However, the company's California Comprehensive Compliance Program declaration, which references HHS-OIG Guidance, is explicitly limited to California activities.
2
Kind to Animals
0
No specific, concrete data points regarding Amylyx Pharmaceuticals (AMLX.US) and its performance on 'Kind to Animals' KPIs were found in the provided articles. , from Amylyx itself, explicitly states 'No data' for all relevant animal welfare metrics.
1
Articles and discuss the FDA's plans to phase out animal testing but explicitly state that no data specific to AMLX.US is mentioned.
2
No War, No Weapons
0
No evidence available to assess Amylyx Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, quantitative data points related to planet-friendly business practices, such as carbon emissions, renewable energy use, water consumption, waste diversion, or environmental certifications, were found in the provided articles for Amylyx Pharmaceuticals, Inc. The articles primarily offer general ESG risk ratings and rankings without detailing specific environmental performance metrics.
1
Respect for Cultures & Communities
0
No evidence available to assess Amylyx Pharmaceuticals, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Amylyx Pharmaceuticals provides users with excellent privacy controls, including the right to confirm data collection, access their data, withdraw consent, and request data deletion.
1
Users can also unsubscribe from communications and opt-out of data sharing for marketing or analytics.
2
However, the company's data retention policies include keeping healthcare professional data for the duration of the relationship plus 5 years, and pharmacovigilance data for at least 10 years, which are longer than typical minimal retention periods.
3
The company explicitly states compliance with a wide range of global privacy and data security requirements, including GDPR, FADP, UK GDPR, U.S. state consumer health privacy laws, cGMP, GCPs, and FCPA, and implements standard contractual clauses for international data transfers.
4
The company requires suppliers to provide training programs for their employees and contractors to manage and address the expectations of its Supplier Code, which includes data privacy and security.
5
The company states that personal data is only collected, used, accessed, stored, and disclosed as permitted by agreement and that it will collect personal data for a specific purpose and only process data relevant to that purpose.
6
The company mentions the use of usernames and passwords for accounts.
7
The company requires suppliers to implement information security best practices to protect the confidentiality, integrity, and accessibility of data and assets.
8
The company requires suppliers to develop and implement appropriate business continuity plans and disaster recovery management for operations supporting Amylyx business, and to immediately report security incidents.
9
Zero Waste & Sustainable Products
0
No specific quantitative data on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education is provided in the available articles.
1
While the company adopted a formal ESG charter in 2024 and an ESG Committee in 2023, and adopted a Supplier Code of Conduct in 2024, these actions are related to governance and general sustainability practices rather than specific, measurable waste reduction initiatives or requirements for suppliers regarding waste and recyclability.
2